Suchergebnisse - "Ishihara, Mikiya"

PubPharm (46)

1

Histological Assessment of Synovial Sarcoma Before and After TCR-T Cell Therapy and Cryoablation : A Case Report

enthalten in: Anticancer research | 2023

von Asanuma, K. | Ishihara, M. | Nakamura, T. | +5

2

Safety and Efficacy of NY-ESO-1 Antigen-Specific T-Cell Receptor Gene-Transduced T Lymphocytes in Patients with Synovial Sarcoma : A Phase I/II Clinical Trial

enthalten in: Clinical cancer research : an official journal of the American Association for Cancer Research | 2023

von Kawai, A. | Ishihara, M. | Nakamura, T. | +17

3

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

enthalten in: Breast cancer (Tokyo, Japan) | 2023

von Futamura, M. | Nakayama, T. | Yoshinami, T. | +13

4

The Japanese Breast Cancer Society Clinical Practice Guidelines for systemic treatment of breast cancer, 2022 edition

enthalten in: Breast cancer (Tokyo, Japan) | 2023

von Terada, M. | Ito, A. | Kikawa, Y. | +37

5

αβ-T cell receptor transduction gives superior mitochondrial function to γδ-T cells with promising persistence

enthalten in: iScience | 2023

von Ishihara, M. | Miwa, H. | Fujiwara, H. | +5

6

Ganglioside GD2 Expression Is Associated With Unfavorable Prognosis in Early Triple-negative Breast Cancer

enthalten in: Anticancer research | 2023

von Higashi, C. | Saito, K. | Kozuka, Y. | +8

7

Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316)

enthalten in: Breast cancer | 2023

von Futamura, M. | Nakayama, T. | Yoshinami, T. | +13

8

A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma

enthalten in: International journal of cancer | 2023

von Ishihara, M. | Nishida, Y. | Kitano, S. | +20

9

Chimeric antigen receptor T-cell therapy targeting a MAGE A4 peptide and HLA-A*02:01 complex for unresectable advanced or recurrent solid cancer : protocol for a multi-institutional phase 1 clinical trial

enthalten in: BMJ open | 2022

von Okumura, S. | Ishihara, M. | Kiyota, N. | +18

10

NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndrome

enthalten in: Journal for immunotherapy of cancer | 2022

von Ishihara, M. | Kitano, S. | Kageyama, S. | +23

1
2
3
4
5
Nächster »
[5]